PA

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Karmiris K et al. – Introduction of adalimumab after failure of infliximab therapy resulted in a sustained clinical benefit in two thirds of patients during a median follow–up period of almost 2 years. Discontinuation was directly related to low adalimumab trough serum concentration, which was observed more frequently in patients who developed antibodies against adalimumab.

   

Related Articles

A Case-Control Study on Risk Factors of Osteoporosis in Patients with Crohn's Disease
Archives of Iranian Medicine, 11/13/09    Relevance Score: 69%

Gastrointestinal stromal tumor causing small bowel intussusception in a patient with Crohn's disease
World Journal of Gastroenterology, 11/13/09    Relevance Score: 69%

Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohns disease
Inflammatory Bowel Disease, 11/05/09    Relevance Score: 69%

C-Reactive Protein and Disease Activity in Children with Crohns Disease
Digestive Diseases and Sciences, 10/26/09    Relevance Score: 69%

Malignant Transformation in Perianal Fistulas of Crohns Disease: a Systematic Review of Literature
Journal of Gastrointestinal Surgery, 10/21/09    Relevance Score: 69%

Today in Gastroenterology...keeping you current

Hemorrhagic Gastritis and Duodenitis Following Celiac Plexus Neurolysis
Pain Physician, 11/25/09

Clinical Features of Gastroduodenal Ulcer in Japanese Patients Taking Low-Dose Aspirin
Digestive Diseases and Sciences, 11/25/09

Pilot translational study of dietary vitamin C supplementation in Barretts esophagus
Diseases of the Esophagus, 11/25/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address